Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPC6 | Q9Y210 | 2/20 | 0.43 |
| ▸ | QDPR | P09417 | 2/20 | 0.42 |
| ▸ | CNR2 | P34972 | 4/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.41 |
| ▸ | F10 | P00742 | 2/20 | 0.41 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.41 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5937212 | 0.89 | CHRM4 (0.49) | TRPC6QDPRCHRM4CHRM1 | |
| SCHEMBL6712503 | 0.85 | QDPR (0.54) | TRPC6QDPRPDE4B | |
| SCHEMBL6788764 | 0.80 | HTR4 (0.42) | TRPC6CNR2CHRM4PDE4B | |
| SCHEMBL5900030 | 0.80 | QDPR (0.52) | QDPROPRL1 | |
| SCHEMBL6789169 | 0.77 | HTR6 (0.46) | CNR2 | |
| SCHEMBL5900037 | 0.77 | MEN1 (0.40) | QDPRCHRM4CHRM1PDE4B | |
| SCHEMBL6710666 | 0.77 | CHRM4 (0.49) | TRPC6QDPRCHRM4CHRM1 | |
| SCHEMBL6788769 | 0.76 | HRH3 (0.42) | CHRM4PDE4B | |
| SCHEMBL6707225 | 0.74 | CHRM4 (0.47) | TRPC6QDPRACACBCHRM4CHRM1 | |
| SCHEMBL6712471 | 0.74 | F10 (0.43) | CNR2OPRL1F10ACACBCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040147557-A1 | Aryl piperidine derivatives as inducers of ldl-receptor expression | BOUILLOT ANNE (FR) | 2004-07-29 | — | — | US | disclosed |
| EP-1351937-A1 | ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002055497-A1 | ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147557-A1 | Aryl piperidine derivatives as inducers of ldl-receptor expression | NR1H2, NR1H3, NR1H4 | TRPC6 924/4885QDPR 1864/4885CNR2 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.